Cargando…
RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers
In 2013 the European Medicine Agency (EMA) restricted the indication for anti-EGFR targeted therapy to metastatic colorectal cancer (mCRC) with a wild-type RAS gene, increasing the need for reliable RAS mutation testing. We evaluated the completeness and reproducibility of RAS-testing in the Netherl...
Autores principales: | Boleij, Annemarie, Tops, Bastiaan B.J., Rombout, Paul D.M., Dequeker, Elizabeth M., Ligtenberg, Marjolijn J.L., van Krieken, J. Han |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558179/ https://www.ncbi.nlm.nih.gov/pubmed/25944693 |
Ejemplares similares
-
RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres
por: Boleij, Annemarie, et al.
Publicado: (2016) -
The homogeneous mutation status of a 22 gene panel justifies the use of serial sections of colorectal cancer tissue for external quality assessment
por: Dijkstra, Jeroen R., et al.
Publicado: (2015) -
RAS testing in metastatic colorectal cancer: advances in Europe
por: Van Krieken, J Han JM, et al.
Publicado: (2015) -
Reducing versus Embracing Variation as Strategies for Reproducibility: The Microbiome of Laboratory Mice
por: Witjes, Vera M., et al.
Publicado: (2020) -
Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non–Small-Cell Lung Cancer in the Netherlands
por: Wolff, Henri B., et al.
Publicado: (2022)